Pfizer ( (PFE) ) has been popular among investors this week. Here is a recap of the key news on this stock.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Pfizer has recently reported solid third-quarter earnings, meeting revenue expectations and surpassing earnings per share predictions. This strong financial performance was attributed to reduced research and development expenses and a lower effective tax rate, leading to an upward revision of the full-year earnings guidance. Despite these positive results, analysts such as Courtney Breen from Bernstein and Carter Gould from Cantor Fitzgerald have maintained a Hold rating on Pfizer, citing ongoing challenges like delays in key pipeline projects and patent pressures.
Morgan Stanley’s Terence Flynn also maintained a Hold rating on Pfizer with a price target of $32.00, while the stock closed at $24.30 last Tuesday. The consensus among analysts is a Hold rating with an average price target of $28.86, indicating an 18.3% upside from current levels. The cautious outlook reflects uncertainties in Pfizer’s growth trajectory despite its strategic positioning and recent financial gains.